AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03153085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1401(HF10)
Description: 1x10\^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10\^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration.
Study NCT03153085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Study NCT02046811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation and education (PAE)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
Study NCT02046811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAE plus physician activation (PAE + MD)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
Study NCT02046811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAE physician activation, plus teledermoscopy (PAE +MD +TD)
Description: Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
Study NCT03894644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation technology
Description: The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
Study NCT03894644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation technology
Description: The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
Study NCT02952469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (68Ga)PSMA-HBED-CC
Description: Experimental radiotracer for imaging prostate cancer
Study NCT03321149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RiseTx
Description: Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
Study NCT04080739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivicaine 0.2%
Description: 2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
Study NCT02354872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Counseling
Description: The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
Study NCT03530839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrodesis
Description: see study group description
Study NCT03530839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection arthroplasty
Description: see study group description
Study NCT01004809 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT03904290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PFO Closure
Description: Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
Study NCT01907230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
Study NCT00871208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altabax (R)
Description: Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
Study NCT00871208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle and Locoid lipocream (R)
Description: The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
Study NCT02333903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity
Description: 1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises.
Study NCT00754078 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Tomotherapy
Description: 30 fractions of tomotherapy treatment
Study NCT00445432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
Study NCT00445432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
Study NCT00956423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-intensity aerobic and resistance training
Description: Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
Study NCT00956423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity stretching
Description: Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
Study NCT02721342 — intervention group
Intervention type: DRUG
Intervention: Ramipril, Irbesartan and Atorvastin
Study NCT04680572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: arthroplasty for fracture neck of femur
Study NCT03850873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616
Description: TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
Study NCT03098212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
Study NCT00694200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 50 mg 3 times a week
Study NCT00694200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg IV every 14 days
Study NCT01981902 — intervention group
Intervention type: DEVICE
Intervention: Non-Invasive Optical Spectroscopic
Description: Non-Invasive Optical Spectroscopic
Study NCT01452516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nanOss Bioactive Bone void filler
Description: Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
Study NCT01452516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interbody FCage
Description: Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
Study NCT00029003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00029003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02054052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
Study NCT01564043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website and pedometer
Description: use of pedometer and website
Study NCT01057680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Powder, 0.1 g per day, 12 months
Study NCT01057680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar placebo
Description: powder, 0.1 g/day, 12 months
Study NCT03759392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil
Description: Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
Study NCT03759392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo twice daily for up to 20 weeks
Study NCT03101605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning teaching module
Description: As described
Study NCT03101605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard teaching method
Description: As described
Study NCT03746847 — intervention group
Intervention type: DRUG
Intervention: Gallium-68 DOTATATE
Description: Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
Study NCT02593617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Addiction Profile Index
Study NCT02593617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol Use Disorders Identification Test
Study NCT02593617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barratt Impulsiveness Scale
Study NCT02593617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zuckerman Sensation Seeking Scale
Study NCT02593617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Energy Drink Consumption Questionnaire
Study NCT00419497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic diet vs Mediterranean diet
Description: Prudent diets with or without grains and dairy
Study NCT02399137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141
Study NCT02399137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02354872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: No Treatment
Study NCT03450382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hans Kai Education
Description: 9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
Study NCT05532202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICU Mom and Baby Net
Description: See arm descriptions.
Study NCT05532202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NICU Developmental Awareness System
Description: See arm description.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: painDETECT Questionnaire
Description: This self-report questionnaire consists of 7 questions that address the quality of neuropathic pain syndromes. The first 5 questions ask about the gradation of pain, question 6 asks about the pain course pattern and question 7 asks about radiating pain. There are 4 additional questions (not counted in the total score) which asks the subject to rate their pain now and over the last 4 weeks and to mark on a body chart if there is pain radiating into other parts of the body.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pain Catastrophizing Scale
Description: The PCS is a 13-item self-report scale. It asks subjects to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the end points (0) not at all and (4) all the time. The PCS yields a total score and three subscale scores assessing rumination, magnification, and helplessness.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pain Intensity Scale, Pain Interference Scale, Pain Behavior Scale
Description: The 3-item, self-report Pain Intensity assesses how much a person hurts. The first 2 items assess pain intensity over the past 7 days; the last item asks subject to rate pain intensity right now. The 4-item, self-report Pain Interference measures the consequences of pain on relevant aspects of subject's life. It includes impairment in subject's social, cognitive, emotional, physical, \& recreational activities. It also incorporates items about sleep and enjoyment of life. It assesses pain interference over the past 7 days.~The 7-item, self-report Pain Behavior measures behaviors that typically indicate to others that an individual is experiencing pain. Measures include observations (sighing, crying), behaviors (resting, guarding, facial expressions, asking for help), \& verbal reports of pain. It assesses pain interference over the past 7 days.~All three scales, derived from the Patient Reported Outcomes Measurement Information System (PROMIS), are not disease specific.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Beck Depression Inventory
Description: The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory
Description: The BDI is a widely used instrument that has been used in both clinical and non-clinical setting measuring depressive symptoms. It is a 21 item questionnaire with 4-5 responses for each question. Responses are coded 0-3 for the 4 point scales. The 5 point scales include an additional 2a and 2b response code. The symptom categories reflect overt behavioral manifestations of depression. The instrument has both a high degree of reliability and validity (Beck, Ward, Mendelson, Mock \& Erbaugh, 1961).
Study NCT01577758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 30-minute infusion on Day 1 of each treatment cycle
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
Study NCT02459977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab induction therapy
Study NCT02459977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No basiliximab
Description: No basiliximab induction therapy
Study NCT02459977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: kidney transplantation
Study NCT02459977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: kidney transplantation
Study NCT01865162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
Study NCT01071928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
Study NCT01071928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
Study NCT00984854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study NCT00984854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study NCT00984854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study NCT00984854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvidex
Description: Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Description: 100 mm line scale that is subject administered to subjectively rate current pain symptoms. The subject will be instructed to draw a single vertical line that best describes current state.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.
Study NCT02608463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient's Global Impression of Change Scale & Clinical Global Impression-Global Improvement Scale
Description: The PGIC gives a global rating of change in symptoms, activities, emotion, and overall quality of life related to the subject's pain condition. This is a self-rated scale.~The CGI-I gives a global rating of the improvement/change in the symptoms since the last study visit. This is administered by the MD.
Study NCT02608463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
Study NCT03386487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 04457845
Description: Study medication will be administered at 4mg by mouth daily for eight weeks.
Study NCT03386487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator will be administered by mouth daily for eight weeks.